CA3141271A1 - Continuous process for the preparation of anticholinergic drugs - Google Patents
Continuous process for the preparation of anticholinergic drugs Download PDFInfo
- Publication number
- CA3141271A1 CA3141271A1 CA3141271A CA3141271A CA3141271A1 CA 3141271 A1 CA3141271 A1 CA 3141271A1 CA 3141271 A CA3141271 A CA 3141271A CA 3141271 A CA3141271 A CA 3141271A CA 3141271 A1 CA3141271 A1 CA 3141271A1
- Authority
- CA
- Canada
- Prior art keywords
- bromide
- process according
- anticholinergic agent
- anticholinergic
- continuous flow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT115583A PT115583B (pt) | 2019-06-17 | 2019-06-17 | Processo contínuo para a preparação de medicamentos anticolinérgicos |
| PT115583 | 2019-06-17 | ||
| PCT/GB2020/051448 WO2020254791A1 (en) | 2019-06-17 | 2020-06-16 | Continuous process for the preparation of anticholinergic drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3141271A1 true CA3141271A1 (en) | 2020-12-24 |
Family
ID=71120199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3141271A Pending CA3141271A1 (en) | 2019-06-17 | 2020-06-16 | Continuous process for the preparation of anticholinergic drugs |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220251078A1 (https=) |
| EP (1) | EP3982923B1 (https=) |
| JP (2) | JP2022549545A (https=) |
| KR (1) | KR20220024433A (https=) |
| CN (1) | CN114206863A (https=) |
| AU (1) | AU2020296972B2 (https=) |
| CA (1) | CA3141271A1 (https=) |
| IL (1) | IL288972A (https=) |
| PT (1) | PT115583B (https=) |
| WO (1) | WO2020254791A1 (https=) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6908928B2 (en) | 2000-10-12 | 2005-06-21 | Bi Pharma Kg. | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
| UY28871A1 (es) | 2004-04-27 | 2005-11-30 | Glaxo Group Ltd | Antagonistas del receptor de acetilcolina muscarinico |
| JP2008540367A (ja) * | 2005-05-02 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規結晶性臭化チオトロピウム |
| WO2006117299A2 (en) | 2005-05-02 | 2006-11-09 | Boehringer Ingelheim International Gmbh | Novel crystalline forms of tiotropium bromide |
| RU2453547C2 (ru) | 2005-12-19 | 2012-06-20 | Сикор Инк. | Новые формы тиотропия бромида и способы их получения |
| US8163913B2 (en) | 2005-12-19 | 2012-04-24 | Sicor Inc. | Forms of tiotropium bromide and processes for preparation thereof |
| JP5333342B2 (ja) | 2009-06-29 | 2013-11-06 | 株式会社デンソー | 半導体装置 |
| SMT201700269T1 (it) * | 2011-12-22 | 2017-07-18 | Cerbios Pharma Sa | Procedimento in continuo per l'alchilazione di ammine terziarie cicliche |
| PT106142B (pt) | 2012-02-10 | 2014-07-18 | Hovione Farmaci Ncia S A | Processo para a preparação de brometo de tiotrópio |
| BR112015003101B1 (pt) * | 2012-08-15 | 2022-06-14 | Glaxo Group Limited | Processo para a preparação de um composto |
| CZ27764U1 (cs) | 2014-08-22 | 2015-02-02 | Zentiva, K.S. | uMethanolový solvát umeclidinium bromidu |
| PT108370B (pt) * | 2015-03-30 | 2018-10-25 | Hovione Farm S A | Processo de preparação de brometo de aclidínio |
| EP3248970A1 (en) | 2016-05-27 | 2017-11-29 | Zentiva K.S. | Forms of umeclidinium bromide |
| PT109740B (pt) | 2016-11-14 | 2020-07-30 | Hovione Farmaciencia Sa | Processo para a preparação de brometo de umeclidínio |
-
2019
- 2019-06-17 PT PT115583A patent/PT115583B/pt active IP Right Grant
-
2020
- 2020-06-16 AU AU2020296972A patent/AU2020296972B2/en active Active
- 2020-06-16 WO PCT/GB2020/051448 patent/WO2020254791A1/en not_active Ceased
- 2020-06-16 KR KR1020227000471A patent/KR20220024433A/ko active Pending
- 2020-06-16 JP JP2021574905A patent/JP2022549545A/ja active Pending
- 2020-06-16 US US17/617,725 patent/US20220251078A1/en active Pending
- 2020-06-16 CA CA3141271A patent/CA3141271A1/en active Pending
- 2020-06-16 CN CN202080049646.2A patent/CN114206863A/zh active Pending
- 2020-06-16 EP EP20734291.6A patent/EP3982923B1/en active Active
-
2021
- 2021-12-13 IL IL288972A patent/IL288972A/en unknown
-
2025
- 2025-02-20 JP JP2025025794A patent/JP2025081547A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT115583A (pt) | 2021-06-03 |
| IL288972A (en) | 2022-02-01 |
| EP3982923B1 (en) | 2024-05-15 |
| EP3982923A1 (en) | 2022-04-20 |
| JP2025081547A (ja) | 2025-05-27 |
| WO2020254791A1 (en) | 2020-12-24 |
| EP3982923C0 (en) | 2024-05-15 |
| KR20220024433A (ko) | 2022-03-03 |
| PT115583B (pt) | 2022-05-02 |
| AU2020296972A1 (en) | 2022-01-20 |
| JP2022549545A (ja) | 2022-11-28 |
| AU2020296972B2 (en) | 2025-04-24 |
| CN114206863A (zh) | 2022-03-18 |
| US20220251078A1 (en) | 2022-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11634377B2 (en) | Fenfluramine compositions and methods of preparing the same | |
| US4608377A (en) | Quaternary 6,11-dihydro-dibenzo-[b,e]-thiepine-11-N-alkylnorscopine ethers having spasmolytic activity | |
| CN104854105B (zh) | 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物 | |
| US11827596B2 (en) | Thyromimetics | |
| CN102639531B (zh) | 噻托溴铵的无水合物 | |
| CN116003387B (zh) | 一种氘代吲唑丙酰胺类化合物、药物组合物和用途 | |
| AU2017376363A1 (en) | Class of bifunctional compounds with quaternary ammonium salt structure | |
| CN102947300A (zh) | 生物碱氨基酯衍生物及其药物组合物 | |
| EP3982923B1 (en) | Continuous process for the preparation of anticholinergic drugs | |
| ES2986962T3 (es) | Proceso continuo para la preparación de fármacos anticolinérgicos | |
| CN111909174B (zh) | 吡啶酮衍生物的晶型及制备方法和应用 | |
| US20220402861A1 (en) | A Crystalline form of (R)-terbutaline Hydrochloride | |
| EP3468949B1 (en) | Crystalline pharmaceutical co-crystals of glycopyrronium bromide with lactose | |
| CN111574529A (zh) | 蕈毒碱受体M3拮抗剂和β2-肾上腺素能受体激动剂桥环衍生物 | |
| KR20130099132A (ko) | 4-[2-디메틸아미노-1-(1-하이드록시사이클로헥실)에틸]페닐 4-메틸벤조에이트 하이드로클로라이드의 다형체, 이의 제조 방법 및 이의 용도 | |
| JP2022549545A5 (https=) | ||
| HK1181769A (en) | Process for the preparation of glycopyrronium chloride | |
| HK1193086B (en) | Mixed crystal agomelatine (form-viii), preparation method and use thereof and pharmaceutical composition containing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220718 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240815 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250203 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250526 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250526 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250529 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250529 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250724 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251110 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260107 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260107 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260107 |